Stoke Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Stoke Therapeutics (Nasdaq: STOK) announced CEO Edward M. Kaye, M.D., will present at two investor conferences. The events include the Stifel 3rd Annual CNS Day on March 31, 2021, at 2:00 PM ET, and the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 12:45 PM ET. Both presentations will be available via live audio webcast on the company's investor site, with replays accessible for 30 days post-event. Stoke Therapeutics focuses on treating severe diseases through RNA-based medicines, including its lead compound STK-001 for Dravet syndrome.

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences, which will each be conducted in a fireside chat format:

Stifel 3^rd Annual CNS Day
Date: Wednesday, March 31, 2021
Time: 2:00 p.m. ET

20^th Annual Needham Virtual Healthcare Conference
Date: Thursday, April 15, 2021
Time: 12:45 p.m. ET

A live audio webcast of each fireside chat will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the fireside chats.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company’s first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company’s belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005229/en/

FAQ

When will Stoke Therapeutics present at the Stifel 3rd Annual CNS Day?

Stoke Therapeutics will present at the Stifel 3rd Annual CNS Day on March 31, 2021, at 2:00 PM ET.

What is the date and time for the Needham Virtual Healthcare Conference presentation?

The Needham Virtual Healthcare Conference presentation will occur on April 15, 2021, at 12:45 PM ET.

How can I watch the Stoke Therapeutics investor presentations?

You can watch the presentations via live audio webcast on the Stoke Therapeutics investor website.

What is the focus of Stoke Therapeutics' research and development?

Stoke Therapeutics focuses on addressing severe diseases by up-regulating protein expression using RNA-based medicines.

What is the lead compound being developed by Stoke Therapeutics?

The lead compound developed by Stoke Therapeutics is STK-001, aimed at treating Dravet syndrome.